(Boursier.com) — The global health agency Unitaid has granted Medincell an additional grant of up to $6 million over 3 years to finance the phase 1 clinical study of the mdc-STM long-acting injectable treatment. If it proves to be safe, effective and well tolerated, it could have a significant impact on the transmission of malaria in vulnerable populations residing in the most affected areas.
“We are delighted that our long-acting injectable technology, which has reached commercial stage following the approval of our first treatment by the US FDA, has the potential to address major global health challenges. Renewed support of Unitaid is essential to moving this project forward. It allows us to capitalize on our internal expertise in regulatory development and to continue our collaboration with the members of the consortium, the IRD, the IRSS and the CIRDES, in order to carry out further studies”, comments Christophe Douat, Chairman of the Management Board of Medincell, who concludes: “Our formulation of ivermectin active for three months, if it proves to be safe and effective, will have the potential to have a significant impact on populations suffering from malaria.
Based on Medincell’s BEPO technology, mdc-STM is an injectable formulation of ivermectin active for 3 months aimed at combating the transmission of malaria. A previous grant of $6.4 million was awarded in March 2020 by Unitaid to finance the research, formulation and preclinical studies of the program, carried out by Medincell and the members of the consortium gathered around the project: the IRD, the IRSS and the CIRDES.
Medincell is committed to combating major global health threats, such as malaria, which remains endemic in 85 countries representing 50% of the world’s population. According to WHO estimates, 249 million people were infected worldwide in 2022, 94% of them in Africa, leading to 580,000 deaths in this region.
©2024 Boursier.com